HUMA
HUMA clinical trials: Humacyte, Inc.
Every trial on ClinicalTrials.gov where Humacyte, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 15
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
HUMA on the catalyst calendar · HUMA registry changes
- Primary completion Not registeredNo phase registeredNCT07141641Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis AccessHumacyte, Inc. · Vascular DiseasesTemporarily not availableHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2030Sponsor estimatePhase 4NCT07762794Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury...Humacyte, Inc. · Vascular InjuryNot yet recruitingHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07762313An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc. · Vascular TraumaNot yet recruitingHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2019ActualPhase 3NCT02644941Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisHumacyte, Inc. · Renal FailureCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2030Sponsor estimatePhase 2NCT07730528Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery...Humacyte, Inc. · Coronary Artery DiseaseNot yet recruitingHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2023ActualPhase 2/Phase 3NCT03005418Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaHumacyte, Inc. · TraumaCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT05908084To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisHumacyte, Inc. · End Stage Renal Disease (ESRD)Active, not recruitingHUMALeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2024ActualPhase 3NCT03183245Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisHumacyte, Inc. · Renal FailureCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03631056Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesHumacyte, Inc. · Vascular System InjuriesApproved for marketingHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2020ActualPhase 2NCT02887859Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADHumacyte, Inc. · Peripheral Artery DiseaseCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 26, 2023ActualNo phase registeredNCT05873959An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian...Humacyte, Inc. · TraumaCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2016ActualNo phase registeredNCT01872208Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PADHumacyte, Inc. · Peripheral Arterial DiseaseCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualNo phase registeredNCT01744418Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRDHumacyte, Inc. · End-stage Renal DiseaseCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2021ActualPhase 2NCT04135417Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisHumacyte, Inc. · Renal FailureCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 28, 2016ActualPhase 1NCT01840956Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal DiseaseHumacyte, Inc. · End-stage Renal DiseaseCompletedHUMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner